![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Salarius Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing potential new cancer medicines for patients in need of new treatment options. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader. Salarius Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing potential new cancer medicines for patients in need of new treatment options. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
Patients were treated in the dose-escalation portion of the Phase 1/2 study evaluating seclidemstat in combination with azacitidine Investigators reported a 43% overall response rate among 14...
HOUSTON, June 12, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.82 | 35.3448275862 | 2.32 | 7.2 | 1.45 | 18879466 | 2.88290402 | CS |
4 | 0.82 | 35.3448275862 | 2.32 | 7.2 | 1.35 | 6657067 | 2.77326702 | CS |
12 | 2.6224 | 506.646058733 | 0.5176 | 7.2 | 0.3868 | 2173897 | 2.75117969 | CS |
26 | 2.591 | 471.948998179 | 0.549 | 7.2 | 0.3868 | 1038872 | 2.62941085 | CS |
52 | 2.27 | 260.91954023 | 0.87 | 7.2 | 0.3868 | 537449 | 2.54314079 | CS |
156 | -18.61 | -85.5632183908 | 21.75 | 30 | 0.3868 | 524819 | 9.24277617 | CS |
260 | -346.86 | -99.1028571429 | 350 | 356.125 | 0.3868 | 643023 | 24.65246946 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions